Last Updated: November 16, 2026

Details for Patent: 9,421,192

« Back to Dashboard


Which drugs does patent 9,421,192 protect, and when does it expire?

Patent 9,421,192 protects DAKLINZA and is included in one NDA.

This patent has sixty-eight patent family members in thirty-one countries.

Summary for Patent: 9,421,192
Title:Hepatitis C virus inhibitors
Abstract:The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s):Makonen Belema, Van N. Nguyen
Assignee: Bristol Myers Squibb Co
Application Number:US14/934,538
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

US Patent 9,421,192: Daclatasvir Patent Scope, HCV Claims, Exclusivity and Generic Risk

US Patent 9,421,192 covers daclatasvir dihydrochloride, the active pharmaceutical ingredient marketed as Daklinza for hepatitis C virus treatment. Its claims are narrow at the compound level but broad in treatment sequencing and combination use. Claim 1 protects the specific daclatasvir salt. Claims 2 through 8 protect administering that compound for HCV infection, including use with interferons, ribavirin, polymerase inhibitors, protease inhibitors and other anti-HCV agents.

The patent does not claim a broad class of NS5A inhibitors, all daclatasvir salts, a finished tablet, a manufacturing process, or every possible HCV regimen. Its principal commercial value is protection of the daclatasvir molecule and selected combination-treatment uses.

What drug does US Patent 9,421,192 protect?

The compound in claim 1 is daclatasvir dihydrochloride, also known as BMS-790052. Daclatasvir is a direct-acting antiviral that inhibits the HCV NS5A protein. The approved product is Daklinza, developed by Bristol-Myers Squibb.

Item Analysis
Active ingredient Daclatasvir
Salt claimed Dihydrochloride
Development code BMS-790052
Brand Daklinza
Viral target HCV NS5A
Drug class Direct-acting antiviral
Molecular type Small molecule
Claim 1 Specific daclatasvir dihydrochloride compound
Claims 2-8 HCV treatment and combination methods
Regulatory pathway New drug application, not a biologics license application

FDA approved Daklinza in 2015 in combination with sofosbuvir for certain patients with chronic HCV genotype 1 or 3 infection. The label later reflected additional clinical and treatment information.[2]

What does claim 1 cover?

Claim 1 is a product claim directed to one chemically defined compound: daclatasvir dihydrochloride.

The claim identifies:

  • The complete stereochemical configuration of the molecule.
  • The biphenyl core.
  • Two imidazole rings.
  • Two pyrrolidine-containing substituents.
  • The methyl carbamate groups.
  • The branched methyl-containing amino-acid-derived portions.
  • The dihydrochloride salt form.

This is a species claim rather than a broad Markush claim. It does not expressly cover every compound having the same pharmacophore or every HCV NS5A inhibitor.

Why the salt limitation matters

The claim is directed to the dihydrochloride salt. A generic applicant seeking to market daclatasvir in a different salt, polymorph, solvate or co-crystal would need to assess whether the alternative form nevertheless falls within the claim under literal infringement or the doctrine of equivalents.

The wording does not expressly claim:

  • Free-base daclatasvir.
  • Daclatasvir acetate, sulfate or other salts.
  • All hydrates or solvates.
  • A specific crystal polymorph.
  • Particle size or solid-state characteristics.
  • A tablet, capsule or injectable dosage form.

If a separate patent claims a particular polymorph, formulation or manufacturing process, that patent could create additional barriers even if the product is outside claim 1.

How broad are the HCV treatment claims?

Claim 2 covers administering a therapeutically effective amount of daclatasvir dihydrochloride to a patient with HCV infection. The claim does not limit the patient by genotype, fibrosis stage, prior treatment history, cirrhosis status or route of administration.

That creates a broad method-of-treatment perimeter relative to the approved label. The claim language potentially reaches use in:

  • Different HCV genotypes.
  • Treatment-naive and treatment-experienced patients.
  • Patients with or without cirrhosis.
  • Various treatment durations.
  • Different dosage regimens.
  • Combination or monotherapy settings, subject to the claim structure and applicable clinical-use facts.

The phrase "therapeutically effective amount" is functional. It does not specify a numerical dose in the supplied claim text. The scope therefore depends on whether the administered amount is intended to produce a therapeutic HCV effect.

What does claim 3 add?

Claim 3 requires daclatasvir plus one or two additional compounds having anti-HCV activity. The additional agent may be administered:

  • Before daclatasvir.
  • After daclatasvir.
  • Simultaneously with daclatasvir.

The claim covers sequential and concurrent combination treatment. It is not restricted to a fixed-dose combination product.

What does claim 4 add?

Claim 4 requires that at least one additional anti-HCV compound be interferon or ribavirin.

This captures historical HCV treatment combinations, including daclatasvir used with ribavirin or interferon-based regimens. It does not require both interferon and ribavirin.

What does claim 5 add?

Claim 5 narrows the interferon category to:

  • Interferon alpha 2B.
  • Pegylated interferon alpha.
  • Consensus interferon.
  • Interferon alpha 2A.
  • Lymphoblastoid interferon tau.

This is a closed selection from the broader interferon concept in claim 4.

What does claim 6 add?

Claim 6 covers combinations with a range of immunomodulatory, antiviral and host-targeting agents, including:

  • Interleukin 2.
  • Interleukin 6.
  • Interleukin 12.
  • Agents that enhance a type 1 helper T-cell response.
  • Interfering RNA.
  • Antisense RNA.
  • Imiquimod.
  • Ribavirin.
  • IMPDH inhibitors.
  • Amantadine.
  • Rimantadine.

The claim is commercially less important than the daclatasvir product claim because several listed agents are obsolete or uncommon in modern HCV treatment. It may still have relevance to historical use, patent enforcement theories and combination research.

What do claims 7 and 8 add?

Claims 7 and 8 cover combination therapy with an agent that inhibits specified HCV or host targets.

Claim 7 identifies:

  • HCV metalloprotease.
  • HCV serine protease.
  • HCV polymerase.
  • HCV helicase.
  • HCV NS4B.
  • HCV entry.
  • HCV assembly.
  • HCV egress.
  • HCV NS5A.
  • IMPDH.

Claim 8 narrows the additional agent to an inhibitor of:

  • HCV serine protease; or
  • HCV polymerase.

These claims can reach combinations involving different direct-acting antiviral classes, including protease inhibitors and polymerase inhibitors. They do not require that the additional compound be marketed, approved, or identified by a particular chemical name in the claim text.

How does the claim hierarchy affect infringement risk?

The claims form a descending hierarchy:

Claim Scope Commercial significance
1 Daclatasvir dihydrochloride compound Primary API protection
2 Use of daclatasvir for HCV infection Broad treatment-use protection
3 Daclatasvir plus one or two anti-HCV agents Combination-use protection
4 Claim 3 with interferon or ribavirin Historical combination coverage
5 Claim 4 with specified interferons Narrow interferon subset
6 Claim 3 with specified immune or antiviral agents Alternative combination coverage
7 Claim 3 with inhibitors of listed HCV or host targets Mechanism-based combination coverage
8 Claim 3 with serine-protease or polymerase inhibitor Narrower DAA combinations

A product that contains daclatasvir dihydrochloride may implicate claim 1 without relying on any treatment indication. A product that avoids claim 1 through a different salt may still face method-of-use risk if the marketed use practices claim 2 or a dependent combination claim.

What patents protect daclatasvir beyond US 9,421,192?

Daclatasvir's patent estate is likely to include several categories:

Patent category Typical subject matter Relevance
Core compound patents Daclatasvir and related NS5A compounds Highest API risk
Salt patents Dihydrochloride and other pharmaceutical salts Salt-selection risk
Polymorph patents Crystal forms, hydrates and solvates Solid-state protection
Formulation patents Tablets, excipients and dosage forms Product-specific risk
Method patents HCV treatment and combination therapy Label and induced-infringement risk
Manufacturing patents Intermediates, coupling reactions and purification Supply-chain and process risk
Combination patents Daclatasvir with sofosbuvir or other DAAs Regimen-specific risk

US Patent 9,421,192, based on the supplied claims, is primarily a compound and treatment-method patent. The claims do not establish coverage of a specific tablet formulation or manufacturing route.

A complete freedom-to-operate review must separate patents that claim the API from patents that claim the approved product, dosage form, polymorph, synthesis or labeled indication. A generic applicant may avoid one category while remaining exposed to another.

When does US Patent 9,421,192 lose exclusivity?

The patent was issued on Aug. 23, 2016. Patent expiration depends on the earliest effective nonprovisional filing date, applicable priority claims, patent-term adjustment and any terminal disclaimer. The grant date alone does not establish the expiration date.

For US pharmaceutical patents, the ordinary statutory term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and patent-term extension under 35 U.S.C. §§ 154 and 156.[3]

The relevant exclusivity analysis is:

Exclusivity type Effect
Patent term Bars infringing manufacture, use, sale or importation
FDA new-drug exclusivity Separate regulatory exclusivity period
Orphan-drug exclusivity Applies only if the product received orphan designation and approval
Pediatric exclusivity Can add six months to certain listed protections
Orange Book listing Links listed patents to ANDA certification obligations
Patent-term extension May extend one qualifying patent for regulatory review time

Daclatasvir was approved in 2015, but approval does not itself determine the expiration of US 9,421,192. The patent's front page, USPTO Patent Center records and FDA Orange Book listing must be reconciled before setting a definitive launch date.

What is the Orange Book status of US 9,421,192?

The supplied claims do not establish whether US 9,421,192 is currently listed in the FDA Orange Book for Daklinza. Orange Book listing is a regulatory-record question, not a conclusion that can be drawn from claim language alone.

If listed against the daclatasvir product, the patent could require an ANDA applicant to submit one of the following certifications:

  • Paragraph I: no patent information has been submitted.
  • Paragraph II: the patent has expired.
  • Paragraph III: the applicant will not market before expiration.
  • Paragraph IV: the patent is invalid, unenforceable or will not be infringed.

A Paragraph IV certification can trigger patent litigation if the NDA holder or patent owner files suit within the statutory period. The commercial effect depends on the specific NDA, listed patent, certification date and litigation outcome.[4]

What generic entry risks exist for daclatasvir?

The main generic-entry risks are different for the API, salt, treatment indication and formulation.

API and salt risk

A generic daclatasvir product using the claimed dihydrochloride form faces the clearest literal-infringement risk under claim 1, assuming the patent remains enforceable and unexpired.

A different salt may reduce literal product-claim exposure but does not automatically eliminate:

  • Equivalence arguments.
  • Method-of-use exposure.
  • Separate salt or polymorph patents.
  • FDA pharmaceutical-equivalence requirements.
  • Manufacturing-process patent exposure.

Method-of-use risk

Claims 2 through 8 may create risk for a product label that instructs use of daclatasvir for HCV infection or use with another anti-HCV agent. A generic applicant may seek a section viii statement and omit patented indications where FDA requirements permit. That strategy depends on the listed patent claims, the approved labeling and whether the remaining label still induces infringement.[5]

Combination-product risk

The combination claims are most relevant to regimens involving:

  • Daclatasvir plus ribavirin.
  • Daclatasvir plus interferon.
  • Daclatasvir plus an HCV protease inhibitor.
  • Daclatasvir plus an HCV polymerase inhibitor.
  • Daclatasvir plus another NS5A-directed agent.

A label that recommends or describes a patented combination can create exposure even if the generic product is chemically identical to the reference product only in the daclatasvir component.

Does biosimilar law apply to daclatasvir?

No. Daclatasvir is a chemically synthesized small molecule, not a biologic subject to the Biologics Price Competition and Innovation Act biosimilar pathway.

The relevant US entry route is generally an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, or, in some circumstances, a 505(b)(2) application. The applicant must assess pharmaceutical equivalence, bioequivalence, labeling, patent certifications and any applicable regulatory exclusivity.[4]

Biosimilar interchangeability, reference-product exclusivity under the Public Health Service Act and biologic patent dance procedures are not the governing framework for daclatasvir.

Which companies are challenging the daclatasvir patent estate?

The supplied claim text does not identify an ANDA filer, Paragraph IV notice, district-court action, appellate decision or settlement agreement. Patent ownership, FDA listing and litigation history must be verified from USPTO, FDA and PACER records before attributing a challenge to a specific company.

No litigation or settlement conclusion should be inferred solely from the existence of claims 1 through 8.

How strong is the patent estate for daclatasvir?

The strongest feature is claim 1's direct coverage of the named active pharmaceutical ingredient in a defined salt form. A generic product that uses the same daclatasvir dihydrochloride API would face a direct product-claim analysis.

The treatment claims provide secondary protection but are more vulnerable to:

  • Prior-art arguments involving HCV combination therapy.
  • Written-description and enablement challenges across broad target classes.
  • Label carve-outs.
  • Non-infringing treatment indications.
  • Changes in standard-of-care regimens.
  • Questions over whether a physician, patient or manufacturer performs the claimed steps.

The claims do not, on their face, provide strong protection for a new formulation, polymorph or manufacturing process unless separate claims in the patent or related patents do so.

What licensing and commercial exposure matter?

Bristol-Myers Squibb developed daclatasvir and commercialized Daklinza. Daclatasvir was positioned as part of the direct-acting antiviral market, where competition included sofosbuvir, ledipasvir, ombitasvir, paritaprevir, ritonavir, dasabuvir, elbasvir, grazoprevir and velpatasvir.

The principal commercial exposure is the US and international daclatasvir franchise rather than a broad platform-technology royalty stream. Licensing, regional commercialization and generic settlements must be analyzed agreement by agreement. The patent claims alone do not establish royalty obligations, authorized-generic arrangements or launch dates.

Key Takeaways

  • US Patent 9,421,192 claims daclatasvir dihydrochloride and HCV treatment methods.
  • Claim 1 is the most commercially important claim because it directly targets the API in a specified salt form.
  • Claims 2 through 8 cover HCV treatment and combinations with interferon, ribavirin, protease inhibitors, polymerase inhibitors and other antiviral or immunomodulatory agents.
  • The patent does not, based on the supplied claims, expressly cover every daclatasvir salt, polymorph, formulation or manufacturing process.
  • Daclatasvir is a small molecule, so generic entry proceeds through the ANDA framework rather than biosimilar law.
  • Orange Book listing, Paragraph IV challenges, litigation and settlements cannot be established from the claim text alone.
  • Definitive expiration analysis requires the patent's priority chain, term adjustment, terminal-disclaimer status and any patent-term extension.
  • Generic risk is highest for a product using daclatasvir dihydrochloride and carrying an HCV treatment label that practices the claimed methods.

FAQs

Is US Patent 9,421,192 a daclatasvir patent?

Yes. The claimed compound is daclatasvir dihydrochloride, also known as BMS-790052.

Does the patent cover sofosbuvir?

No. The supplied claims do not claim sofosbuvir as a compound. They may reach certain combinations involving an HCV polymerase inhibitor, depending on how the combination claims are construed.

Does the patent cover all NS5A inhibitors?

No. Claim 1 is directed to the specifically recited daclatasvir compound. Claims 2 through 8 require use of that compound.

Can a generic company avoid the patent by using a different daclatasvir salt?

Possibly, but a different salt would require a separate infringement and validity analysis. Method claims, salt patents, polymorph patents and equivalence theories may remain relevant.

Is a Paragraph IV certification required for every daclatasvir ANDA?

Not necessarily. The required certification depends on the patents listed for the reference product, their status, the ANDA's proposed labeling and whether the applicant can use a section viii statement or another permissible route.

References

  1. United States Patent No. 9,421,192. (2016). United States Patent and Trademark Office.

  2. U.S. Food and Drug Administration. (2015). Daklinza (daclatasvir) prescribing information. FDA.

  3. United States Code, 35 U.S.C. §§ 154, 156.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

  5. United States Code, 21 U.S.C. § 355; 21 C.F.R. § 314.94.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,421,192

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ⤷  Start Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-001 Jul 24, 2015 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y METHOD OF INHIBITING HEPATITIS C VIRUS ⤷  Start Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ⤷  Start Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-002 Jul 24, 2015 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y METHOD OF INHIBITING HEPATITIS C VIRUS ⤷  Start Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-003 Apr 13, 2016 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY ⤷  Start Trial
Bristol-myers Squibb DAKLINZA daclatasvir dihydrochloride TABLET;ORAL 206843-003 Apr 13, 2016 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y METHOD OF INHIBITING HEPATITIS C VIRUS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,421,192

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2049522 ⤷  Start Trial C300713 Netherlands ⤷  Start Trial
European Patent Office 2049522 ⤷  Start Trial CA 2015 00003 Denmark ⤷  Start Trial
European Patent Office 2049522 ⤷  Start Trial C20150003 00128 Estonia ⤷  Start Trial
European Patent Office 2049522 ⤷  Start Trial PA2015006 Lithuania ⤷  Start Trial
European Patent Office 2049522 ⤷  Start Trial 92635 Luxembourg ⤷  Start Trial
European Patent Office 2049522 ⤷  Start Trial 15C0007 France ⤷  Start Trial
European Patent Office 2049522 ⤷  Start Trial 1590007-9 Sweden ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.